Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Official Title

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Principal Investigator

Luke, Jason

Brief Summary

This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B
works compared with pembrolizumab in treating patients with stage III-IV melanoma that has
been removed by surgery but is likely to come back or spread. High-dose recombinant
interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies,
such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.
It is not yet known whether high-dose recombinant interferon alfa-2B is more effective than
pembrolizumab in treating patients with melanoma.